Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2021

View Archived Issues

IL-27 drives metabolic programs and its targeting aids in the treatment of obesity

FBXO22 sensitizes tumor cells to DNA damage by PD-L1 degrading

Novel syngeneic bladder cancer model using organoid line with specific gene deletions

Ube Industries patents integrin alphav antagonists

Suzhou Zelgen Biosciences synthesizes new GTPase KRAS mutant inhibitors

Glixogen Therapeutics identifies GLI1 inhibitors

Jiangsu Chia Tai Tianqing Pharmaceutical Group presents SOS1 inhibitors

Shanghai Zheye Biotechnology divulges new SGLT-1 inhibitors

RAGE-229 inhibits RAGE-DIAPH1 binding and lessens diabetic complications in mice

[68Ga]SP-94 shows excellent uptake in GRP78-positive HCC tumors

GP73 analysis aids in the diagnosis of NASH and staging of hepatic fibrosis

Targeting TWEAK shows potential as alternative therapeutic strategy for psoriasis

Oragenics reports on SARS-CoV-2 vaccine formulations in hamster challenge study

MALT1 mutant mice reveal role of E3 ligase TRAF6 in peripheral immune tolerance

Stepwise engineered IL-37-Fc-fusion protein shows improved therapeutic likeness

Small molecule allows targeted degradation of repeat expansion in vitro and in vivo in ALS models

Chimeric obtains option to license CORE-NK platform from Case Western Reserve University

DREADD approach calms neuropsychiatric dread circuits in primates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...